508 related articles for article (PubMed ID: 11781649)
1. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
2. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation.
Platzbecker U; Bandt D; Thiede C; Helwig A; Freiberg-Richter J; Schuler U; Plettig R; Geissler G; Rethwilm A; Ehninger G; Bornhäuser M
Transplantation; 2001 Apr; 71(7):880-5. PubMed ID: 11349720
[TBL] [Abstract][Full Text] [Related]
3. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation.
Cesaro S; Zhou X; Manzardo C; Buonfrate D; Cusinato R; Tridello G; Mengoli C; Palù G; Messina C
J Clin Virol; 2005 Oct; 34(2):129-32. PubMed ID: 16157264
[TBL] [Abstract][Full Text] [Related]
4. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
5. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Kiehl MG; Basara N
Blood; 2001 Sep; 98(5):1626; author reply 1628. PubMed ID: 11547768
[No Abstract] [Full Text] [Related]
6. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
7. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
8. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Ljungman P; Deliliers GL; Platzbecker U; Matthes-Martin S; Bacigalupo A; Einsele H; Ullmann J; Musso M; Trenschel R; Ribaud P; Bornhäuser M; Cesaro S; Crooks B; Dekker A; Gratecos N; Klingebiel T; Tagliaferri E; Ullmann AJ; Wacker P; Cordonnier C
Blood; 2001 Jan; 97(2):388-92. PubMed ID: 11154213
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
Hubacek P; Keslova P; Formankova R; Pochop P; Cinek O; Zajac M; Lochmanova J; Stary J; Sedlacek P
Pediatr Transplant; 2009 Nov; 13(7):919-22. PubMed ID: 19067913
[TBL] [Abstract][Full Text] [Related]
10. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Ketteler M; Preuschof L; Mertz A; Stöffler-Meilicke M; Schäfer H; Distler A; Offermann G
Clin Nephrol; 2000 Nov; 54(5):418-24. PubMed ID: 11105806
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
AIDS; 2000 Jul; 14(11):1571-81. PubMed ID: 10983644
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection following stem cell transplantation.
Einsele H; Hebart H
Haematologica; 1999 Jun; 84 Suppl EHA-4():46-9. PubMed ID: 10907466
[No Abstract] [Full Text] [Related]
13. Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study.
Bosi A; Bartolozzi B; Vannucchi AM; Orsi A; Guidi S; Rossi Ferrini P
Haematologica; 2002 Apr; 87(4):446-7. PubMed ID: 11940492
[No Abstract] [Full Text] [Related]
14. Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Castagnola E; Miano M; Morreale G; Cristina E; Chierici M; Lanino E
Blood; 2001 Sep; 98(5):1627-8; author reply 1628-9. PubMed ID: 11547769
[No Abstract] [Full Text] [Related]
15. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
16. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
17. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients.
Nagafuji K; Aoki K; Henzan H; Kato K; Miyamoto T; Eto T; Nagatoshi Y; Ohba T; Obama K; Gondo H; Harada M
Bone Marrow Transplant; 2004 Nov; 34(10):909-14. PubMed ID: 15361907
[TBL] [Abstract][Full Text] [Related]
18. Management of cytomegalovirus disease.
Danner SA
AIDS; 1995 Dec; 9 Suppl 2():S3-S8. PubMed ID: 8775800
[TBL] [Abstract][Full Text] [Related]
19. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
[TBL] [Abstract][Full Text] [Related]
20. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
